checkAd
    Startseite > Aktien > Aldeyra Therapeutics > Nachrichten
    Aldeyra Therapeutics Aktie
    3,6960
     
    EUR
    -2,30 %
    -0,0870 EUR
    Letzter Kurs 30.04.24 Tradegate
    3,6370
     
    EUR
    1.099 STK
    Geldkurs 30.04.24
    3,7560
     
    EUR
    1.064 STK
    Briefkurs 30.04.24
    ISIN: US01438T1060 · WKN: A111X8 · SYM: 137 · USA

    Neueste Nachrichten

    Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
    25.04.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
    18.04.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
    28.03.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    06.02.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
    04.01.24 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
    19.12.23 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
    18.12.23 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
    27.11.23 · Business Wire (engl.) · Aldeyra Therapeutics
    Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
    01.11.23 · Business Wire (engl.) · Aldeyra Therapeutics
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)
    28.09.23 · Business Wire (engl.) · Aldeyra Therapeutics
    ALDEYRA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
    28.09.23 · Business Wire (engl.) · Aldeyra Therapeutics
    Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit
    26.09.23 · Business Wire (engl.) · Aldeyra Therapeutics